September 2 - 3, 2020


Converge. Create. Elevate.


Senior VP, Global Patient Solutions, Gilead


Clifford Samuel is Senior VP, Global Patient Solutions, handling more than 127 countries around the world. He joined Gilead Sciences in 1996 as member of the company's commercial organization to support the introduction of Gilead's first commercial product.

Today, he oversees the ongoing development and implementation of innovative manufacturing, distribution and business models to make the company's HIV, viral hepatitis and anti-fungal medicines available at affordable prices in resource-limited and emerging economies. Additionally, he builds strategic partnerships around the world, including collaborations with governments, non-governmental organizations and generic drug manufacturers to ensure the achievement of large-scale access to medicines.

Under his leadership, Gilead has entered into generic licensing agreements with companies in China, India and South Africa, creating a competitive market for generic HIV and hepatitis B drugs that has dramatically reduced prices and helped to deliver medicines to more than 15 million people-in-need across the Global Patient Solutions geographies. Starting in 2014, Gilead also extended licensing agreements to 11 Indian, Egypt and Pakistan manufacturers to scale up access to its hepatitis C treatments in 106 countries.

He earned his Bachelors in Mechanical Engineering from New Jersey Institute of Technology (NJIT), serves as a member of the Honor Program Board, was awarded the Edward F. Weston Medal for Professional Achievement in 2010 and received an Honorary PhD (Honoris Causa) in 2019. In recognition for the pioneering of new and developing fields of technology, making major advancements in traditional fields of engineering, and developing/implementing innovative approaches to engineering education, he was inducted into the National Academy of Engineers in October 2019.